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Stability of Extemporaneously Prepared Sodium Benzoate Oral Solution
Abstract
Purpose: Sodium benzoate (NaC7H5O2), a common food preservative, is the salt form of benzoic acid. It is
used as an alternative treatment in patients with hepatic encephalopathy or urea cycle disorders as it is
believed help stimulate ammonia removal via a non-urea cycle based pathway. Despite its use, sodium
benzoate is not an FDA approved medication and has no commercially available oral formulations, although
an IV formulation is available in combination with sodium phenylacetate (Ammonul®). The objectives of this
study were to prepare a sodium benzoate solution and determine the stability of an extemporaneously
prepared oral solution over a 90-day period.
Methods: An oral solution of sodium benzoate was prepared and a 1 ml sample was withdrawn from each
bottle immediately after preparation and at 7 and 14 days and assayed for drug concentration by stability-
indicating high performance liquid chromatography. Stability of sodium benzoate solution will be defined as
maintenance of greater than or equal to 90 percent of the initial concentration.
Results: The sodium benzoate maintained 96% and 93% of the initial concentrationt at 7 and 14 days,
respectively. Therefore, sodium benzoate oral solution in cherry syrup is stable for a minimum of 14 at room
temperature.
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• Urea cycle disorders (UCD) occurs in 1: 8500 births and leads to an accumulation of 
ammonia due to a deficiency of the enzyme(s) utilized in the urea cycle  
• Depending on the severity, UCD can lead to growth suppression, neurologic changes, 
seizures, coma, and death 
• Sodium benzoate is believed to stimulate ammonia removal via the Hippurate
pathway, independent of the urea cycle
• Sodium benzoate/sodium phenylacetate (Ammonul®) is an FDA approved IV 
formulation approved for the treatment of UCD 
• There is currently no FDA approved oral formulation of sodium benzoate 
commercially available; although many pediatric patients utilize compounded 
solutions for chronic therapy  
• Determine the 90-day stability of sodium benzoate oral solution, 
defined as the retention of at least 90% of the initial concentration 
Peak Summary
Day 0 Chromatogram
The Urea Cycle
AL – Argininosuccinate Lyase AS - Argininosuccinate Synthase    OTC – Orthinine Transcarbamylase
/ - Potential enzyme deficiency present in urea cycle disorders 
Sample Preparation:
• Twenty five grams of sodium benzoate was added to a 
beaker containing 50 ml of sterile water and stirred until 
dissolved 
• The resulting solution was filtered via Whatman filter 
paper and added to a 4-oz amber bottle pre-calibrated 
to 100 ml 
• The beaker which contained the sodium benzoate 
solution was rinsed with cherry syrup and added to the 
amber bottle until final volume of solution was 100 ml
• Final solution concentration was 250 mg/ml
Preparation for Analysis: 
• Prepared samples for shaken for 1 minute before 
sampling
• A 1 ml aliquot was removed from each sample and 
diluted to 100 ml with diluent (50:50 mixture of sterile 
water and acetonitrile) for a concentration of 2.5 mg/ml 
• A 0.1 ml aliquot of the 2.5 mg/ml solution was further 
diluted to 100 ml with diluent for a final concentration of 
2.5 mcg/ml 
• Samples were filtered through a 45-micron filter 
• Samples were analyzed at days 0,7, and 14
Analysis: 
• Samples were analyzed via a Shimadzu HPLC with a 
C18 column and mobile phase of 30:70 acetonitrile and 
20-mM monobasic potassium phosphate adjusted to pH 
of 2.5 with phosphoric acid
• A 15 υL sample was injected and analyzed with the 
detector set at 230 nm
• The samples were run for 15 minutes with a mobile 
phase rate of 1 ml/min 
• The chromatogram was analyzed using LC solutions 
version 1.25
Sample 1 Sample 2 Sample 3
Day 0 Day 7 Day 14 Day 0 Day 7 Day 14 Day 0 Day 7 Day 14
Retention
time 
(min)
5.620 5.606 5.661 5.620 5.603 5.642 5.622 5.605 5.369
Maximum 
Intensity 
(mV)
26751 23251 24460 24726 24101 24468 24438 24108 24202
Area 215016 213917 211816 219287 218913 219817 221916 220093 219824
Difference = 10.92% Difference = 2.97% Difference = 2.65%
0
1
2
3
4
5
6
7
1 2 3
C
on
ce
nt
ra
ti
on
 (
m
cg
/m
L
)
Sample
Day 0
Day 7
Day 14
• Sodium benzoate oral solution in cherry syrup is appears to be stable for at a 
minimum of 14 days at room temperature. 
• Further stability analysis will be conducted at days 30, 60, and 90. 
• A forced degradation analysis will also be conducted by exposing the samples to 
acidic and basic pH, hydrogen peroxide, direct sunlight, and prolonged exposure to 
60oC.   
Sodium Benzoate Concentration
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